The Peri Decade

The same ten years

Roughly between 35 and 47, several things start happening at once.

Your hormones begin fluctuating — not declining smoothly, but swinging, which is why perimenopause feels so much less predictable than the tidy diagrams suggest. Oestrogen and progesterone both move, and breast tissue is unusually sensitive to both because it is dense with receptors for them. Breasts change in this decade. They get tender, they change size, the texture shifts across the month, and lumpiness comes and goes.

In the same decade, your screening life begins. The US Preventive Services Task Force now recommends that women start screening mammography at 40, every two years, through to 74 — a change from its previous position, which left the decision to individual discretion between 40 and 49. So around the time the hormonal shifts start, a letter arrives telling you to book something you have never booked before.

And in the same decade, if you have that mammogram, you will receive a second piece of paper telling you whether your breast tissue is dense. Since September 2024, the FDA has required every mammography facility in the US to tell you. Most women who get that letter have no idea what to do with it.

These are not three separate stories happening to three separate groups of women. They are one story, happening to the same woman, in the same ten years. Nobody has been treating them that way.

Why now

Two things make this more urgent than it would have been a decade ago.

The first is that breast cancer in younger women is rising, and the shape of the rise is specific. Researchers at Washington University School of Medicine in St. Louis analysed data from more than 217,000 US women diagnosed between 2000 and 2019 and found that incidence among women aged 20–49 rose slowly — about 0.24% a year — until 2016, and then accelerated sharply to 3.76% a year through 2019. The increase was driven almost entirely by oestrogen-receptor-positive tumours. Oestrogen-receptor-negative incidence actually fell over the same period.

That is a rise concentrated in exactly the hormone-sensitive category, in exactly the age band where the hormonal conversation is happening. It does not mean perimenopause causes breast cancer — it does not, and nothing here should be read that way. It means the two topics are adjacent in a way that makes their separation in public conversation look increasingly odd.

The second is that the hormone therapy conversation has changed fast. In November 2025 the FDA moved to remove the boxed warnings about cardiovascular disease, breast cancer and dementia from menopausal hormone therapy products, on the grounds that the original warnings rested on a study whose design didn't match how HRT is actually prescribed today. That is a significant correction. It is also being read online as "HRT is now proven safe," which is not what the FDA said, and is not what the evidence shows.

Somewhere between "never take it" and "everyone should take it" is an actual decision, and it depends partly on your own breast cancer risk — which most women have never calculated.

What we're publishing

Over the next ten days we are publishing a series on the questions this decade actually raises:

• Is it peri, or is it something? Perimenopause explains most breast changes in your forties. Not all of them. Where the line sits, and what to do about the ones that fall on the wrong side of it.

• Breast tissue, explained. Seven things about your own anatomy that almost nobody tells you.

• The 40th birthday checklist. Three things to do in the year you turn 40.

• The HRT decision. Not a position. The framework, and the input almost nobody brings to the conversation.

• What actually happens in a mammogram. The appointment, demystified.

Plus a collaboration with Lauren O'Connell — Beauty Editor at Cosmopolitan Middle East, founder of 3 of Cups, and a breast cancer survivor who started formulating during chemotherapy.

What this isn't

This is not a campaign about fear. Most breast changes in your forties are hormonal and benign, and any piece of content that makes you forget that has failed at its job. The message throughout is check, don't panic — and the check is usually the thing that lets you stop worrying.

It is also not a sales exercise. There are no products in any of this, no discount attached, and no pink ribbon anywhere. NOOD makes bras and covers and tape. We know a fair amount about breasts. We do not know more than your doctor, and nothing here is a substitute for talking to one.

What we can do is put a few good conversations in one place, for free, and leave them up.

This article is for general information and is not medical advice. Speak to a healthcare professional about your own situation.

Sources: US Preventive Services Task Force, Breast Cancer: Screening (April 2024). FDA, National Dense Breast Reporting requirements (effective September 2024). Toriola et al., JAMA Network Open, January 2024. FDA press announcement on menopausal hormone therapy labelling, November 2025.